NCT00479388View on ClinicalTrials.gov

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,216

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

October 31, 2008

Conditions

Primary HypercholesterolemiaMixed Dyslipidemia

Interventions

DRUG

Comparator: simvastatin

simvastatin (20mg to 40mg) for 12 weeks.

DRUG

niacin (+) laropiprant

One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.

DRUG

Comparator: atorvastatin calcium

atorvastatin calcium (20mg to 40mg) for 12 weeks.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00479388 - Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) | Biotech Hunter | Biotech Hunter